FDA Accepts Alkermes Resubmission of New Drug Application for ALKS 3831
- FDA Sets PDUFA Target Action Date of June 1, 2021 -
DUBLIN, Dec. 29, 2020 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company s New Drug Application (NDA) resubmission for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and adults with bipolar I disorder, and has assigned the application a new Prescription Drug User Fee Act (PDUFA) target action date of June 1, 2021.
The FDA classified the resubmission as a complete, Class 2 response to the Complete Response Letter (CRL) issued in November 2020, following a remote review of records requested under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the FDCA ) relating to the manufacture of ALKS 3831 at the company s Wilmington, OH facility. Subsequent to Alkermes resubmission of the NDA, the FDA issued a new request
Okul müdürü hakkýnda soruþturma izni Bakanlýkta deðil valilikte memurlar.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from memurlar.net Daily Mail and Mail on Sunday newspapers.
If it’s a single claim by one customer, go to Step 6.
If it’s a joint claim by two customers, go to Step 8.
Step 6
Use Function MANAGE VERIFICATION FAILURES to check which residency rules the customer has failed verification on. To do this
select the record you want to investigate
select [Investigate]. You will be taken to the Investigate Verification Failure screen
check which residency rules the customer has failed verification on
Note: Check Household Notes to check if the claim has already been referred to the Persons From Abroad (PFA) Team or International Team. If the claim has been referred to the